Literature DB >> 18974198

The effect of Fc glycan forms on human IgG2 antibody clearance in humans.

Xiaoyu Chen1, Y Diana Liu, Gregory C Flynn.   

Abstract

Several studies using a variety of approaches have investigated the impact of the Fc glycan structure on IgG clearance rates. Most, but not all, of these studies have concluded that glycan structural differences do not affect clearance. Here we investigated the impact of glycan on the clearance of a human antibody in humans. To monitor glycan-dependent changes, a human IgG2 was affinity purified in a single step from serum samples from a human pharmacokinetic study. The glycan profile from the purified antibody samples was determined by RP-HPLC/MS analysis of the 2-aminobenzamide-labeled glycans. Relative levels of high-mannose species (M6-M9) decreased over circulation time. Differences in the individual high-mannose structural isoform clearance rates were measured from extracted ion current profiles. Similar changes to the glycan profile could be achieved through incubation of the antibody in serum in vitro, suggesting that the changes observed in vivo were the result of glycan cleavage, not differential antibody clearance. These results confirm that antibody clearance is not significantly affected by the Fc glycan structure and provide evidence for the presence of circulating mannosidase activity in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974198     DOI: 10.1093/glycob/cwn120

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  36 in total

1.  Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.

Authors:  Ramil F Latypov; Sabine Hogan; Hollis Lau; Himanshu Gadgil; Dingjiang Liu
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

Review 2.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 3.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

4.  4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.

Authors:  Alain Beck; Sherif Hanala; Janice M Reichert
Journal:  MAbs       Date:  2009-03-20       Impact factor: 5.857

Review 5.  Advances in the assessment and control of the effector functions of therapeutic antibodies.

Authors:  Xu-Rong Jiang; An Song; Svetlana Bergelson; Thomas Arroll; Bhavin Parekh; Kimberly May; Shan Chung; Robert Strouse; Anthony Mire-Sluis; Mark Schenerman
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

6.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 8.  Assessing monoclonal antibody product quality attribute criticality through clinical studies.

Authors:  Andrew M Goetze; Matthew R Schenauer; Gregory C Flynn
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

9.  High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

Authors:  Mohammad A Alsenaidy; Jae Hyun Kim; Ranajoy Majumdar; David D Weis; Sangeeta B Joshi; Thomas J Tolbert; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-09-24       Impact factor: 3.534

10.  Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys.

Authors:  Maya K Leabman; Y Gloria Meng; Robert F Kelley; Laura E DeForge; Kyra J Cowan; Suhasini Iyer
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.